‘No Surprises’ as Ozanimod Holds up in RMS Extension Trial

Commenting on the findings for Medscape Medical News, John R. Corboy, professor of neurology at the University of Colorado School of Medicine in Aurora, Colorado, said many formularies limit access to ozanimod “as it has no obvious benefit in comparison to generic fingolimod, which is significantly cheaper.”